Skip to Content
MilliporeSigma
  • Nesprin-2 giant safeguards nuclear envelope architecture in LMNA S143F progeria cells.

Nesprin-2 giant safeguards nuclear envelope architecture in LMNA S143F progeria cells.

Human molecular genetics (2007-09-21)
Sebastian Kandert, Yvonne Lüke, Tobias Kleinhenz, Sascha Neumann, Wenshu Lu, Verena M Jaeger, Martina Munck, Manfred Wehnert, Clemens R Müller, Zhongjun Zhou, Angelika A Noegel, Marie-Christine Dabauvalle, Iakowos Karakesisoglou
ABSTRACT

The S143F lamin A/C point mutation causes a phenotype combining features of myopathy and progeria. We demonstrate here that patient dermal fibroblast cells have dysmorphic nuclei containing numerous blebs and lobulations, which progressively accumulate as cells age in culture. The lamin A/C organization is altered, showing intranuclear and nuclear envelope (NE) aggregates and presenting often a honeycomb appearance. Immunofluorescence microscopy showed that nesprin-2 C-terminal isoforms and LAP2alpha were recovered in the cytoplasm, whereas LAP2beta and emerin were unevenly localized along the NE. In addition, the intranuclear organization of acetylated histones, histone H1 and the active form of RNA polymerase II were markedly different in patient cells. A subpopulation of mutant cells, however, expressing the 800 kDa nesprin-2 giant isoform, did not show an overt nuclear phenotype. Ectopic expression of p.S143F lamin A in fibroblasts recapitulates the patient cell phenotype, whereas no effects were observed in p.S143F LMNA keratinocytes, which highly express nesprin-2 giant. Overexpression of the mutant lamin A protein had a more severe impact on the NE of nesprin-2 giant deficient fibroblasts when compared with wild-type. In summary, our results suggest that the p.S143F lamin A mutation affects NE architecture and composition, chromatin organization, gene expression and transcription. Furthermore, our findings implicate a direct involvement of the nesprins in laminopathies and propose nesprin-2 giant as a structural reinforcer at the NE.